Jonathan Edwards
"Gibberish"
- Messages
- 5,256
I don't really understand the significance of this b/c according to my doctor, you do not truly know if RTX has worked in any given patient until about six months after B-Cell depletion. So a patient could not have any improvement at 3-mos but then have an improvement at 6-mos and this is considered successful. Why would the Fluge & Mella Study not follow this same pattern and assume that improvements at 6-mos were due to chance?
What I think your doctor means is that in other conditions where rituximab is known to work it may take 6 months before you can be sure whether or not there is improvement. I am not sure I would agree with that (as the person who probably has more experience with the drug in autoimmunity than anyone). In most autoimmune conditions some improvement is evident at 3 months. It may be that your doctor is simply quoting the results of the Norwegian study - which did seem to show that nothing much happened until 6 months. But the whole problem is that we do not know whether ornate that was a fluke.
The real problem is that Fluge and Mella used a scoring system that worked over a six week period so that the score at 3 months was actually for 6 to 12 weeks - which in retrospect one would predict was too early. But when they set up the rules for the trial they were not familiar with treating autoimmune disease.
So it is all very complicated but the bottom line is nobody can be sure the results of that trial mean anything.
Would this be the same for patients in the study (or who try RTX in general) who have had symptoms that did not fluctuate (or did every single patient who was selected have a relapsing/remitting type of illness)? I can only speak for myself in that when I had an improvement to a specific symptom, it was striking and noticeable both to myself and to all who know me (vs. other symptoms which have not yet improved). I have not been able to try RTX yet (so for me it was the combination of MCAS meds & IVIG) but none of my doctors would ever attribute what they are seeing to chance or coincidence. I have no guarantee that RTX will work for me but if it does, we will know it has worked vs. it being chance.
I am afraid it does not work like that. Any properly trained doctor will accept that improvement following a treatment may be due to chance or coincidence. That is the whole basis for the complex rules of trial design. If you get rituximab and get better nobody can tell if it is due to the rituximab. Doctors can never know that. They just work on the basis that if they use a reliably tested treatment that the chances are it was the drug that was responsible.
I don't understood how this could possibly be the case? Many physicians assume or wish the patient can get better with "wishful thinking" or CBT/GET or mindfulness/yoga or all kinds of things but when someone actually uses a specific treatment and then gets better and remains better, wouldn't it be from that treatment (especially if the person has been progressively getting worse for several years and did not have a fluctuating form of their illness)? Thanks in advance.
Again, I am afraid that getting better from wishful thinking occurs with all treatments. It is called the placebo effect and for the rituximab trial from Norway there was a 19% placebo response if I remember rightly.